Little attention was given to the interaction between tumor and stromal cells in urothelial bladder carcinoma (UBC). While recent studies point towards the existence of different fibroblast subsets, no comprehensive analyses linking different fibroblast markers to UBC patient survival have been performed so far. Through immunohistochemical analysis of five selected fibroblast markers, namely alpha smooth muscle actin (ASMA), CD90/Thy-1, fibroblast activation protein (FAP), platelet derived growth factor receptor-alpha and -beta (PDGFRa,-b), this study investigates their association with survival and histopathological characteristics in a cohort of 344 UBC patients, involving both, muscle-invasive and non-muscle-invasive cases. The data indicates that combinations of stromal markers are more suited to identify prognostic patient subgroups than single marker analysis. Refined stroma-marker-based patient stratification was achieved through cluster analysis and identified a FAP-dominant patient cluster as independent marker for shorter 5-year-survival (HR(95% CI)2.25(1.08-4.67), p = 0.030). Analyses of interactions between fibroblast and CD8a-status identified a potential minority of cases with CD90-defined stroma and high CD8a infiltration showing a good prognosis of more than 80% 5-year-survival. Presented analyses point towards the existence of different stroma-cell subgroups with distinct tumor-modulatory properties and motivate further studies aiming to better understand the molecular tumor-stroma crosstalk in UBC.

Charles University Faculty of Medicine in Pilsen Institut of Biology Plzen Czech Republic

Department of Immunology Genetics and Pathology Uppsala University Uppsala Sweden

Department of Oncology Pathology Karolinska Institutet Stockholm Sweden

Department of Surgical Sciences Uppsala University Uppsala Sweden

Zobrazit více v PubMed

Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. PubMed DOI

Ploeg M, Aben KKH, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J. Urol. 2009;27:289–293. doi: 10.1007/s00345-009-0383-3. PubMed DOI PMC

Kamat AM, et al. Bladder cancer. Lancet Lond. Engl. 2016;388:2796–2810. doi: 10.1016/S0140-6736(16)30512-8. PubMed DOI

Sanli O, et al. Bladder cancer. Nat. Rev. Dis. Primer. 2017;3:17022. doi: 10.1038/nrdp.2017.22. PubMed DOI

Goulet CR, et al. Cancer-associated fibroblasts induce epithelial-mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling. BMC Cancer. 2019;19:137. doi: 10.1186/s12885-019-5353-6. PubMed DOI PMC

Jordan B, Meeks JJ. T1 bladder cancer: current considerations for diagnosis and management. Nat. Rev. Urol. 2019;16:23–34. doi: 10.1038/s41585-018-0105-y. PubMed DOI

Smith AB, et al. Muscle-invasive bladder cancer: evaluating treatment and survival in the National Cancer Data Base. BJU Int. 2014;114:719–726. doi: 10.1111/bju.12601. PubMed DOI

Burger M, et al. Epidemiology and Risk Factors of Urothelial Bladder Cancer. Eur. Urol. 2013;63:234–241. doi: 10.1016/j.eururo.2012.07.033. PubMed DOI

Liedberg F, et al. Local recurrence and progression of non-muscle-invasive bladder cancer in Sweden: a population-based follow-up study. Scand. J. Urol. 2015;49:290–295. doi: 10.3109/21681805.2014.1000963. PubMed DOI

Miyake M, et al. CXCL1-Mediated Interaction of Cancer Cells with Tumor-Associated Macrophages and Cancer-Associated Fibroblasts Promotes Tumor Progression in Human Bladder Cancer. Neoplasia N. Y. N. 2016;18:636–646. doi: 10.1016/j.neo.2016.08.002. PubMed DOI PMC

Hemdan T, et al. The prognostic value and therapeutic target role of stathmin-1 in urinary bladder cancer. Br. J. Cancer. 2014;111:1180–1187. doi: 10.1038/bjc.2014.427. PubMed DOI PMC

Wang L, et al. EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nat. Commun. 2018;9:3503. doi: 10.1038/s41467-018-05992-x. PubMed DOI PMC

Pfannstiel Carolin, Strissel Pamela L., Chiappinelli Katherine B., Sikic Danijel, Wach Sven, Wirtz Ralph M., Wullweber Adrian, Taubert Helge, Breyer Johannes, Otto Wolfgang, Worst Thomas, Burger Maximilian, Wullich Bernd, Bolenz Christian, Fuhrich Nicole, Geppert Carol I., Weyerer Veronika, Stoehr Robert, Bertz Simone, Keck Bastian, Erlmeier Franziska, Erben Philipp, Hartmann Arndt, Strick Reiner, Eckstein Markus. The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes. Cancer Immunology Research. 2019;7(6):923–938. doi: 10.1158/2326-6066.CIR-18-0758. PubMed DOI

Alexa A, Baderca F, Lighezan R, Izvernariu D. Myofibroblasts reaction in urothelial carcinomas. Romanian J. Morphol. Embryol. Rev. Roum. Morphol. Embryol. 2009;50:639–643. PubMed

Schulte J, et al. Expression of the E-cadherin repressors Snail, Slug and Zeb1 in urothelial carcinoma of the urinary bladder: relation to stromal fibroblast activation and invasive behaviour of carcinoma cells. Histochem. Cell Biol. 2012;138:847–860. doi: 10.1007/s00418-012-0998-0. PubMed DOI

Grimm S, et al. Malignancy of bladder cancer cells is enhanced by tumor-associated fibroblasts through a multifaceted cytokine-chemokine loop. Exp. Cell Res. 2015;335:1–11. doi: 10.1016/j.yexcr.2015.04.001. PubMed DOI

Shin K, et al. Hedgehog signaling restrains bladder cancer progression by eliciting stromal production of urothelial differentiation factors. Cancer Cell. 2014;26:521–533. doi: 10.1016/j.ccell.2014.09.001. PubMed DOI PMC

LeBleu, V. S. & Kalluri, R. A peek into cancer-associated fibroblasts: origins, functions and translational impact. Dis. Model. Mech. 11, (2018). PubMed PMC

Kalluri R. The biology and function of fibroblasts in cancer. Nat. Rev. Cancer. 2016;16:582–598. doi: 10.1038/nrc.2016.73. PubMed DOI

Ostman A, Pietras K. Introduction to tumor-stroma interactions. Exp. Cell Res. 2013;319:1595. doi: 10.1016/j.yexcr.2013.05.026. PubMed DOI

Strell C, Rundqvist H, Ostman A. Fibroblasts–a key host cell type in tumor initiation, progression, and metastasis. Ups. J. Med. Sci. 2012;117:187–195. doi: 10.3109/03009734.2012.654859. PubMed DOI PMC

Östman A. Cancer-associated fibroblasts: recent developments and emerging challenges. Semin. Cancer Biol. 2014;25:1–2. doi: 10.1016/j.semcancer.2014.02.004. PubMed DOI

Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. J. Exp. Med. 2014;211:1503–1523. doi: 10.1084/jem.20140692. PubMed DOI PMC

Desmoulière A, Guyot C, Gabbiani G. The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int. J. Dev. Biol. 2004;48:509–517. doi: 10.1387/ijdb.041802ad. PubMed DOI

Özdemir BC, et al. Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival. Cancer Cell. 2014;25:719–734. doi: 10.1016/j.ccr.2014.04.005. PubMed DOI PMC

Yamashita M, et al. Role of stromal myofibroblasts in invasive breast cancer: stromal expression of alpha-smooth muscle actin correlates with worse clinical outcome. Breast Cancer Tokyo Jpn. 2012;19:170–176. doi: 10.1007/s12282-010-0234-5. PubMed DOI

Tsujino T, et al. Stromal myofibroblasts predict disease recurrence for colorectal cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2007;13:2082–2090. doi: 10.1158/1078-0432.CCR-06-2191. PubMed DOI

Costa A, et al. Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer. Cancer Cell. 2018;33:463–479.e10. doi: 10.1016/j.ccell.2018.01.011. PubMed DOI

Kraman M, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science. 2010;330:827–830. doi: 10.1126/science.1195300. PubMed DOI

Feig C, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl. Acad. Sci. USA. 2013;110:20212–20217. doi: 10.1073/pnas.1320318110. PubMed DOI PMC

Chen L, Qiu X, Wang X, He J. FAP positive fibroblasts induce immune checkpoint blockade resistance in colorectal cancer via promoting immunosuppression. Biochem. Biophys. Res. Commun. 2017;487:8–14. doi: 10.1016/j.bbrc.2017.03.039. PubMed DOI

Cremasco V, et al. FAP Delineates Heterogeneous and Functionally Divergent Stromal Cells in Immune-Excluded Breast Tumors. Cancer Immunol. Res. 2018;6:1472–1485. doi: 10.1158/2326-6066.CIR-18-0098. PubMed DOI PMC

Strell Carina, Paulsson Janna, Jin Shao-Bo, Tobin Nicholas P, Mezheyeuski Artur, Roswall Pernilla, Mutgan Ceren, Mitsios Nicholas, Johansson Hemming, Wickberg Sarah Marie, Svedlund Jessica, Nilsson Mats, Hall Per, Mulder Jan, Radisky Derek C, Pietras Kristian, Bergh Jonas, Lendahl Urban, Wärnberg Fredrik, Östman Arne. Impact of Epithelial–Stromal Interactions on Peritumoral Fibroblasts in Ductal Carcinoma in Situ. JNCI: Journal of the National Cancer Institute. 2019;111(9):983–995. doi: 10.1093/jnci/djy234. PubMed DOI PMC

Raz Y, et al. Bone marrow-derived fibroblasts are a functionally distinct stromal cell population in breast cancer. J. Exp. Med. 2018;215:3075–3093. doi: 10.1084/jem.20180818. PubMed DOI PMC

Bartoschek M, et al. Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing. Nat. Commun. 2018;9:5150. doi: 10.1038/s41467-018-07582-3. PubMed DOI PMC

Paulsson J, et al. Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am. J. Pathol. 2009;175:334–341. doi: 10.2353/ajpath.2009.081030. PubMed DOI PMC

Hägglöf C, et al. Stromal PDGFRbeta expression in prostate tumors and non-malignant prostate tissue predicts prostate cancer survival. PloS One. 2010;5:e10747. doi: 10.1371/journal.pone.0010747. PubMed DOI PMC

Ehnman M, et al. Distinct effects of ligand-induced PDGFRα and PDGFRβ signaling in the human rhabdomyosarcoma tumor cell and stroma cell compartments. Cancer Res. 2013;73:2139–2149. doi: 10.1158/0008-5472.CAN-12-1646. PubMed DOI PMC

Frödin M, et al. Perivascular PDGFR-β is an independent marker for prognosis in renal cell carcinoma. Br. J. Cancer. 2017;116:195–201. doi: 10.1038/bjc.2016.407. PubMed DOI PMC

Kilvaer TK, et al. Differential prognostic impact of platelet-derived growth factor receptor expression in NSCLC. Sci. Rep. 2019;9:10163. doi: 10.1038/s41598-019-46510-3. PubMed DOI PMC

Nordby Y, et al. High expression of PDGFR-β in prostate cancer stroma is independently associated with clinical and biochemical prostate cancer recurrence. Sci. Rep. 2017;7:43378. doi: 10.1038/srep43378. PubMed DOI PMC

Corvigno S, et al. Multi-parametric profiling of renal cell, colorectal, and ovarian cancer identifies tumour-type-specific stroma phenotypes and a novel vascular biomarker. J. Pathol. Clin. Res. 2017;3:214–224. doi: 10.1002/cjp2.74. PubMed DOI PMC

Paulsson J, et al. High expression of stromal PDGFRβ is associated with reduced benefit of tamoxifen in breast cancer. J. Pathol. Clin. Res. 2017;3:38–43. doi: 10.1002/cjp2.56. PubMed DOI PMC

Yamaoka R, et al. CD90 expression in human intrahepatic cholangiocarcinoma is associated with lymph node metastasis and poor prognosis. J. Surg. Oncol. 2018;118:664–674. doi: 10.1002/jso.25192. PubMed DOI

Schliekelman MJ, et al. Thy-1+ Cancer-associated Fibroblasts Adversely Impact Lung Cancer Prognosis. Sci. Rep. 2017;7:6478. doi: 10.1038/s41598-017-06922-5. PubMed DOI PMC

Phipps RP, et al. Characterization of two major populations of lung fibroblasts: distinguishing morphology and discordant display of Thy 1 and class II MHC. Am. J. Respir. Cell Mol. Biol. 1989;1:65–74. doi: 10.1165/ajrcmb/1.1.65. PubMed DOI

Saada JI, et al. Subepithelial myofibroblasts are novel nonprofessional APCs in the human colonic mucosa. J. Immunol. Baltim. Md 1950. 2006;177:5968–5979. PubMed

Koumas L, Smith TJ, Phipps RP. Fibroblast subsets in the human orbit: Thy-1+ and Thy-1− subpopulations exhibit distinct phenotypes. Eur. J. Immunol. 2002;32:477–485. doi: 10.1002/1521-4141(200202)32:2<477::AID-IMMU477>3.0.CO;2-U. PubMed DOI

Ranganathan P, Pramesh CS, Aggarwal R. Common pitfalls in statistical analysis: Measures of agreement. Perspect. Clin. Res. 2017;8:187–191. doi: 10.4103/picr.PICR_123_17. PubMed DOI PMC

Ostman A, Augsten M. Cancer-associated fibroblasts and tumor growth–bystanders turning into key players. Curr. Opin. Genet. Dev. 2009;19:67–73. doi: 10.1016/j.gde.2009.01.003. PubMed DOI

Zhuang J, et al. TGFβ1 secreted by cancer-associated fibroblasts induces epithelial-mesenchymal transition of bladder cancer cells through lncRNA-ZEB2NAT. Sci. Rep. 2015;5:11924. doi: 10.1038/srep11924. PubMed DOI PMC

Calvete J, et al. The coexpression of fibroblast activation protein (FAP) and basal-type markers (CK 5/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder. Hum. Pathol. 2019;91:61–68. doi: 10.1016/j.humpath.2019.07.002. PubMed DOI

Herrera M, et al. Cancer-associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients. Cancer Sci. 2013;104:437–444. doi: 10.1111/cas.12096. PubMed DOI PMC

Wikberg ML, et al. High intratumoral expression of fibroblast activation protein (FAP) in colon cancer is associated with poorer patient prognosis. Tumour Biol. J. Int. Soc. Oncodevelopmental Biol. Med. 2013;34:1013–1020. doi: 10.1007/s13277-012-0638-2. PubMed DOI PMC

Mhawech-Fauceglia P, et al. Stromal Expression of Fibroblast Activation Protein Alpha (FAP) Predicts Platinum Resistance and Shorter Recurrence in patients with Epithelial Ovarian Cancer. Cancer Microenviron. Off. J. Int. Cancer Microenviron. Soc. 2015;8:23–31. doi: 10.1007/s12307-014-0153-7. PubMed DOI PMC

Shi M, et al. Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance. World J. Gastroenterol. 2012;18:840–846. doi: 10.3748/wjg.v18.i8.840. PubMed DOI PMC

Kumar A, Bhanja A, Bhattacharyya J, Jaganathan BG. Multiple roles of CD90 in cancer. Tumour Biol. J. Int. Soc. Oncodevelopmental Biol. Med. 2016;37:11611–11622. doi: 10.1007/s13277-016-5112-0. PubMed DOI

Pathology and genetics of tumours of the urinary system and male genital organs:… editorial and consensus conference in Lyon, France, December 14–18, 2002. (IARC Press, (2006).

Boman K, et al. Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer. BMC Urol. 2013;13:17. doi: 10.1186/1471-2490-13-17. PubMed DOI PMC

Lindén M, et al. Proteomic analysis of urinary biomarker candidates for nonmuscle invasive bladder cancer. Proteomics. 2012;12:135–144. doi: 10.1002/pmic.201000810. PubMed DOI

Boman K, et al. Membranous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer. Br. J. Cancer. 2013;108:2321–2328. doi: 10.1038/bjc.2013.215. PubMed DOI PMC

Fristrup N, et al. Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer. Am. J. Pathol. 2012;180:1824–1834. doi: 10.1016/j.ajpath.2012.01.023. PubMed DOI

Mezheyeuski A, et al. Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer. Oncotarget. 2016;7:41948–41958. doi: 10.18632/oncotarget.9632. PubMed DOI PMC

Corvigno S, et al. Markers of fibroblast-rich tumor stroma and perivascular cells in serous ovarian cancer: Inter- and intra-patient heterogeneity and impact on survival. Oncotarget. 2016;7:18573–18584. doi: 10.18632/oncotarget.7613. PubMed DOI PMC

Oguejiofor K, et al. Stromal infiltration of CD8 T cells is associated with improved clinical outcome in HPV-positive oropharyngeal squamous carcinoma. Br. J. Cancer. 2015;113:886–893. doi: 10.1038/bjc.2015.277. PubMed DOI PMC

Thakolwiboon S, et al. Heterogeneity of The CD90+ Population in Different Stages of Hepatocarcinogenesis. J. Proteomics Bioinform. 2014;7:296–302. doi: 10.4172/jpb.1000332. PubMed DOI PMC

Zhu, J., Thakolwiboon, S., Liu, X., Zhang, M. & Lubman, D. M. Overexpression of CD90 (Thy-1) in Pancreatic Adenocarcinoma Present in the Tumor Microenvironment. PLoS ONE9, (2014). PubMed PMC

Henriksson ML, et al. Colorectal Cancer Cells Activate Adjacent Fibroblasts Resulting in FGF1/FGFR3 Signaling and Increased Invasion. Am. J. Pathol. 2011;178:1387–1394. doi: 10.1016/j.ajpath.2010.12.008. PubMed DOI PMC

Miksch RC, et al. Development of a reliable and accurate algorithm to quantify the tumor immune stroma (QTiS) across tumor types. Oncotarget. 2017;8:114935–114944. doi: 10.18632/oncotarget.22932. PubMed DOI PMC

Mohamed M, et al. CD8+ tumor infiltrating lymphocytes strongly correlate with molecular subtype and clinico-pathological characteristics in breast cancer patients from Sudan. Transl. Med. Commun. 2016;1:4. doi: 10.1186/s41231-016-0005-1. DOI